Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: Association with nephritis

Rheumatology

Volumn 46, Issue 11, 2007, Pages 1657-1661

  Quartuccio, L ^a   Fabris, M ^a   Salvin, S ^a   Isola, M ^a   Soldano, F ^a   Falleti, E ^a   Beltrami, C A ^a   De re, V ^a   De Vita, Salvatore ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

B cell; Bone marrow; Clonality; Lymphoma; Mixed cryoglobulinaemia; Nephritis

Indexed keywords

CRYOGLOBULIN; HEPATITIS C ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW; CLINICAL FEATURE; CLONAL VARIATION; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN ULCER;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; BONE MARROW CELLS; CELL DIVISION; CLONE CELLS; CRYOGLOBULINEMIA; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; SKIN ULCER;

EID: 35548954245     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem209     Document Type: Article

References (29)

1. Gorevic PD, Kassab HJ, Levo Y et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;89:287-308.
2. Abel G, Zhang OX, Agnello V. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 1993;36:1341-9.
3. Zaja F, Do Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
4. Sansonno D, De Re V, Lauletta G, Tucci FA, Bolocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
5. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: Efficacy and safety in the lack of steroids. Rheumatology 2006;45:842-6.
6. Ferri C, Sebastani M, Guggioli D et al. Mixed cryoglobulinemia: demographic, clinical, and serological features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74.
7. De Vita S, De Re V, Gasuarotto D et al. Oligoclonal non-neoplastic B-cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pothologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000;43:94-102.
8. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002;55:4-13.
9. De Re V, Sansonno, D, Smula MP et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clenal proliferations. Leukemia 2006;20:1145-54.
10. Monti G, Pioltelli P, Saccardo F et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobullnemias. Arch Intern Med 2005;165:101-5.
11. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögran's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
12. Krishnan J, Danon AD, Frizzera G. Reactive lymphoadenopathies and atypical lymphoproliferative disorders. Am J Clin Pathol 1993;99:385-96.
13. Pileri SA, Roncador G, Ceccarelli C et al. Antigen retrieval techniques in immunohistochomistry: Comparison of different methods. J Pathol 1997;183:116-23.
14. Brouet JC, Clouvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. Am J Med 1974;57:775-88.
15. Monteverde A, Ballare M, Bertoncelli MC et al. Lymphoproliferstion in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S141-7.
16. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World health organization classification of lymphomas: A work in progress. Ann Oncol 1998;9:S25-30.
17. De Vita S, Boiccchi M, Sorrentino D et al. Characterization of prelymphomatous stages of B call lymphoproliferation in Sjögren's syndrome. Arthritis Rheum 1997;40:318-31.
18. De Re V, De Vita S, Sansoono D et al. Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology 2006;45:685-93.
19. Carbonari M, Caprini E, Tedesco T et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: A model of infection-driven tymphomagenesis. J Immunol 2005;174:6632-9.
20. De Vita S, Quartuccio, L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007, (in press).
21. Mazzaro C, Franzin F, Tulissi P et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996;77:2604-13.
22. De Vita S, Quartuccio L. Rituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinaemia. Rheumatology 2006;45:784-5.
23. Saadoun D, Bieche I, Maisonobe T et al. Involvement of chemokines and type-1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005;52:2917-25.
24. Bernacchi E, La, Civita L, Caproni M et al. Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): Could the presence of HCV in skin lesions be related to CD8+ lymphocytes, HLA-DR and ICAM-1 expression? Exp Dermatol 1999;8:480-6.
25. Fabris M, Tolusso B, Sacco S, Quartuccio L, Ferraccioli G, De Vita S. Fibronectin plasma levels and gone polymorphisms in aggressive RA patients treated with anti-TNF-alpha agents. Ann Rheum Dis 2004;3(Suppl. 1):118.
26. Fabris M, Quartuccio L, Sacco S et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hapatitis-C virus infection. Rheumatology 2006;46:37-43.
27. Vallat L, Benhamou Y, Gutierrez M et al. Clonal B cell population in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004;56:3668-78.
28. Roccatello, D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonaphritis. Nephrol Dial Transplant 2004;19:3054-61.
29. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis Rheum 2006;54:3696-706.